Sangamo Therapeutics Stock Forecast, Price & News

Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

Is Sangamo Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sangamo Therapeutics stock.
View analyst ratings for Sangamo Therapeutics or view top-rated stocks.

How has Sangamo Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Sangamo Therapeutics' stock was trading at $7.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SGMO shares have increased by 17.0% and is now trading at $8.21.
View which stocks have been most impacted by COVID-19.

When is Sangamo Therapeutics' next earnings date?

Sangamo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Sangamo Therapeutics.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.01. The biopharmaceutical company had revenue of $28.60 million for the quarter, compared to the consensus estimate of $25.96 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 39.90% and a negative net margin of 167.16%. The firm's quarterly revenue was down 50.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.01) EPS.
View Sangamo Therapeutics' earnings history.

What price target have analysts set for SGMO?

4 analysts have issued 1-year price targets for Sangamo Therapeutics' shares. Their forecasts range from $16.00 to $29.00. On average, they expect Sangamo Therapeutics' stock price to reach $23.00 in the next year. This suggests a possible upside of 180.1% from the stock's current price.
View analysts' price targets for Sangamo Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the following people:

• Alexander D. Macrae, President, Chief Executive Officer & Director
• Prathyusha Durabaibu, Senior VP, Chief Financial & Accounting Officer
• R. Andrew Ramelmeier, Executive Vice President-Technical Operations
• Jason D. Fontenot, Chief Scientific Officer
• Bettina M. Cockroft, Chief Medical Officer & Senior Vice President

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics CEO Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among Sangamo Therapeutics' employees.

Who are some of Sangamo Therapeutics' key competitors?

Some companies that are related to Sangamo Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exact Sciences (EXAS), Repligen (RGEN), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of SGMO's competitors.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.77%), Wasatch Advisors Inc. (7.31%), Credit Suisse AG (2.46%), Dimensional Fund Advisors LP (1.59%), Geode Capital Management LLC (1.51%) and Goldman Sachs Group Inc. (1.13%). Company insiders that own Sangamo Therapeutics stock include Biogen Inc, Gary Loeb, H Stewart Parker, Joseph S Zakrzewski, Rolf Andrew Ramelmeier, Saira Ramasastry and Stephen George Dilly.
View institutional ownership trends for Sangamo Therapeutics.

Which major investors are selling Sangamo Therapeutics stock?

SGMO stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Dimensional Fund Advisors LP, Citigroup Inc., Two Sigma Investments LP, Raymond James & Associates, Two Sigma Advisers LP, Oppenheimer & Co. Inc., and American Century Companies Inc.. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Biogen Inc, Gary Loeb, Rolf Andrew Ramelmeier, and Saira Ramasastry.
View insider buying and selling activity for Sangamo Therapeutics or view top insider-selling stocks.

Which major investors are buying Sangamo Therapeutics stock?

SGMO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Nordea Investment Management AB, Moors & Cabot Inc., Wasatch Advisors Inc., Lombard Odier Asset Management Switzerland SA, UBS Group AG, Renaissance Technologies LLC, and Geode Capital Management LLC. Company insiders that have bought Sangamo Therapeutics stock in the last two years include H Stewart Parker, and Joseph S Zakrzewski.
View insider buying and selling activity for Sangamo Therapeutics or or view top insider-buying stocks.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $8.21.

How much money does Sangamo Therapeutics make?

Sangamo Therapeutics has a market capitalization of $1.20 billion and generates $118.19 million in revenue each year. The biopharmaceutical company earns $-121 million in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does Sangamo Therapeutics have?

Sangamo Therapeutics employs 413 workers across the globe.

When was Sangamo Therapeutics founded?

Sangamo Therapeutics was founded in 1995.

What is Sangamo Therapeutics' official website?

The official website for Sangamo Therapeutics is www.sangamo.com.

Where are Sangamo Therapeutics' headquarters?

Sangamo Therapeutics is headquartered at 7000 MARINA BLVD, BRISBANE CA, 94005.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at [email protected], or via fax at 510-236-8951.